108 related articles for article (PubMed ID: 16087401)
1. TNF-blocking therapies: an alternative mode of action?
Choo-Kang BS; Hutchison S; Nickdel MB; Bundick RV; Leishman AJ; Brewer JM; McInnes IB; Garside P
Trends Immunol; 2005 Oct; 26(10):518-22. PubMed ID: 16087401
[TBL] [Abstract][Full Text] [Related]
2. Immunological therapies for rheumatoid arthritis.
Edwards CJ
Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
[TBL] [Abstract][Full Text] [Related]
3. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
5. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
Mathsson L; Lampa J; Mullazehi M; Rönnelid J
Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis.
Makrygiannakis D; Catrina AI
J Rheumatol; 2012 Apr; 39(4):679-85. PubMed ID: 22422498
[TBL] [Abstract][Full Text] [Related]
7. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
Morović-Vergles J
Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
[TBL] [Abstract][Full Text] [Related]
9. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
[TBL] [Abstract][Full Text] [Related]
11. The immune system and new therapies for inflammatory joint disease.
Oliver SM
Musculoskeletal Care; 2003 Mar; 1(1):44-57. PubMed ID: 20217663
[TBL] [Abstract][Full Text] [Related]
12. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
13. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune diseases induced by TNF-targeted therapies.
Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
[TBL] [Abstract][Full Text] [Related]
15. Cellular mechanisms of TNF function in models of inflammation and autoimmunity.
Apostolaki M; Armaka M; Victoratos P; Kollias G
Curr Dir Autoimmun; 2010; 11():1-26. PubMed ID: 20173385
[TBL] [Abstract][Full Text] [Related]
16. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
Channual J; Wu JJ; Dann FJ
Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
[TBL] [Abstract][Full Text] [Related]
17. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
18. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Brezinschek HP; Brickmann K; Yazdani-Biuki B; Dörner T; Graninger WB; Brezinschek RI
Wien Med Wochenschr; 2006 Jan; 156(1-2):61-7. PubMed ID: 16465615
[TBL] [Abstract][Full Text] [Related]
20. Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue.
Galassi G; Ariatti A; Codeluppi L; Meletti S
Muscle Nerve; 2010 Aug; 42(2):296-8; author reply 298. PubMed ID: 20658603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
